Current Hematologic Malignancy Reports Q1 Unclaimed
Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the diagnosis, treatment, management, and prevention of conditions associated with hematologic malignancy.
Offers the views of experts on current advances in the field of hematologic malignancy
Gathers and highlights important recent papers from a wealth of original publications
Draws on the expertise of authorities in 12 related subject areas It has an SJR impact factor of 0,998.
Current Hematologic Malignancy Reports focuses its scope in these topics and keywords: cell, leukemia, transforming, treatment, relapsed, refractory, chronic, therapy, lymphoblastic, t, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
2690 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
0,998
SJR Impact factor44
H Index31
Total Docs (Last Year)130
Total Docs (3 years)2271
Total Refs402
Total Cites (3 years)130
Citable Docs (3 years)2.83
Cites/Doc (2 years)73.26
Ref/DocOther journals with similar parameters
Journal of Hematology and Oncology Q1
Blood Q1
Blood Cancer Journal Q1
The Lancet Haematology Q1
Leukemia Q1
Compare this journals
Aims and Scope
Best articles by citations
Treatment of Newly Diagnosed Multiple Myeloma in Transplant-Eligible Patients
View moreTreatment of Newly Diagnosed Myeloma in Patients not Eligible for Transplantation
View moreAlternative Donor Transplantation - "Mixing and Matching": the Role of Combined Cord Blood and Haplo-Identical Donor Transplantation (Haplo-Cord SCT) as a Treatment Strategy for Patients Lacking Standard Donors?
View moreRecent Advances in Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia
View moreThe Role of Transplantation in Diffuse Large B-Cell Lymphoma: The Impact of Rituximab Plus Chemotherapy in First-line and Relapsed Settings
View moreThe Value of Patient Reported Outcomes and Other Patient-Generated Health Data in Clinical Hematology
View moreClinical Aspects of Malt Lymphomas
View moreEx Vivo Expansion or Manipulation of Stem Cells to Improve Outcome of Umbilical Cord Blood Transplantation
View moreChronic Myelogenous Leukemia: Monitoring Response to Therapy
View moreChimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You
View moreLessons from ALL-REZ BFM 90: Therapy for Childhood Leukemia Based on Timing and Site of Relapse
View moreMonoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
View moreEpstein-Barr virus-related lymphoproliferative disorders
View moreRecent Developments in Nongastric Mucosa-Associated Lymphoid Tissue Lymphoma
View moreFuture Therapies for the Myeloproliferative Neoplasms
View moreMinimal Residual Disease Assessment in the Context of Multiple Myeloma Treatment
View moreManaging HIV and Hodgkin Lymphoma in the Twenty-first century
View moreLeveraging Hypomethylating Agents for Better MDS Therapy
View moreAnti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma
View moreWhat is the Standard Regimen for Patients with Acute Promyelocytic Leukemia?
View moreNew Immunomodulatory Drugs in Myeloma
View moreSmall Molecule Inhibitors in Chronic Lymphocytic Lymphoma and B Cell Non-Hodgkin Lymphoma
View moreIsolated Extramedullary Relapse in Childhood Acute Lymphocytic Leukemia
View moreNew Treatment Strategies for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
View more
Comments